Full video transcriptClick to expand
Auto-generated transcript of @sevenofandrew's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:001,992 people died by suicide today.
- 0:05As a three-time suicide survivor, I've gotten a lot of messages asking why am I not promoting suicide awareness month?
- 0:15And the reason is because it's stupid.
- 0:241,992 people will die tomorrow by suicide.
- 0:29And after tomorrow's gone, 1,992 people will die by suicide the next day.
- 0:36And the next, and the next, and the next.
- 0:39In long past September, they'll continue to die at an average of 1,992 people.
- 0:45The struggles with suicide far exceeds 30 days in a calendar month.
- 0:54And for most people, highlighting the struggles, just because it's the ninth month of the year, does nothing for them.
- 1:04Because often when it's time for them to talk, they don't have the real resources or the opportunity or sometimes even the bravery, or the bravery of others to actually listen.
- 1:14So yes, it may be good to highlight suicide and the prevention and the awareness.
- 1:25But suicide rates are increasing every year, especially among college-aged women.
- 1:32So the month isn't doing anything.
- 1:39We had a shiny month with some ribbons and some marches and a few social posts.
- 1:47As soon as it's done, those of us who struggle over told, well, you had your month, get over it.
- 1:55And we're forgotten till the next year.
- 1:59And in between that time and every day between 1,992 people die by suicide every single day.
- 2:13To all those who are struggling, I'm going to say the one thing that we all agree on, you're not alone.
GLP-1 drugs and suicide risk: what the data actually shows
Quick answer
This video does not make clinical claims about treatment or medication. It focuses on suicide epidemiology and the adequacy of public health awareness campaigns. Clinicians should be aware that FDA monitoring of GLP-1 receptor agonists for suicidal ideation signals remains relevant context for this platform, and any patient on semaglutide or tirzepatide reporting mood changes should receive a formal mental health screening.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 drugs and suicide risk: what the data actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 drugs and suicide risk: what the data actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 drugs and suicide risk: what the data actually shows" from Andrewwwwwwww. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This video does not make clinical claims about treatment or medication.
The reason this review is not generic is the source wording and the canonical claim label "glp1 i bet you will not forget that statistic anytime soon hopefu." In this clip, the useful excerpt is: "1,992 people died by suicide today." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
This video does not make clinical claims about treatment or medication.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video does not make clinical claims about treatment or medication. It focuses on suicide epidemiology and the adequacy of public health awareness campaigns. Clinicians should be aware that FDA monitoring of GLP-1 receptor agonists for suicidal ideation signals remains relevant context for this platform, and any patient on semaglutide or tirzepatide reporting mood changes should receive a formal mental health screening.
- WHO 2021 data estimates roughly 703,000 global suicide deaths per year, approximately 1,926 per day, making the 1,992 figure a close but slightly high estimate.
- Twenge et al. (2018, Clinical Psychological Science) confirmed significant increases in suicidal ideation among adolescent and young adult females from 2010 to 2015, validating the college-aged women trend claim.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- WHO 2021 data estimates roughly 703,000 global suicide deaths per year, approximately 1,926 per day, making the 1,992 figure a close but slightly high estimate.
- Twenge et al. (2018, Clinical Psychological Science) confirmed significant increases in suicidal ideation among adolescent and young adult females from 2010 to 2015, validating the college-aged women trend claim.
- CDC 2022 data shows the U.S. suicide rate ticked upward after a brief plateau in 2020-2021, meaning 'increasing every year' overstates a real but non-linear long-term trend.
- Pirkis et al. (2021, The Lancet Psychiatry) found awareness campaigns can boost short-term help-seeking but show weak evidence for sustained suicide rate reductions on their own.
- SAMHSA 2022 found 57% of adults who needed mental health services did not receive them, with cost and provider availability as the leading barriers.
- The FDA opened an investigation in 2023 into suicidal ideation reports associated with GLP-1 drugs including semaglutide and liraglutide. The EMA found no confirmed causal link as of early 2024, but the FDA review was still ongoing.
- The 988 Suicide and Crisis Lifeline is available 24 hours a day, 7 days a week in the United States by call or text.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @sevenofandrew actually say?
The creator, who identifies as a three-time suicide survivor, made two specific statistical claims: that 1,992 people die by suicide globally every single day, and that suicide rates are "increasing every year, especially among college-aged women." The broader argument was that a single awareness month is structurally insufficient and that people who struggle are essentially abandoned once September ends. These are substantive claims worth checking, not just vibes.
The emotional core of the video is that performative awareness, "a shiny month with some ribbons and some marches," does not translate into reduced deaths. That is an opinion, but it is one with real data behind it worth examining seriously.
Does the science back this up?
The global figure is roughly accurate. The World Health Organization estimated approximately 703,000 suicide deaths annually as of its 2021 report, which works out to about 1,926 per day. The creator's figure of 1,992 is close, possibly drawn from a slightly older or differently sourced estimate, but it is in the credible range and not fabricated.
On rising rates among college-aged women, the evidence is real and documented. Twenge et al. (2018, Clinical Psychological Science) found significant increases in suicidal ideation and attempts among adolescent and young adult females between 2010 and 2015. The CDC's 2023 Youth Risk Behavior Survey confirmed that female high school and college-age students reported sharply elevated rates of persistent sadness and suicidal ideation compared to male peers. The directional claim is correct.
Whether awareness months work is genuinely contested. A 2021 systematic review by Pirkis et al. in The Lancet Psychiatry found that mass media campaigns can increase help-seeking behavior short-term, but evidence for sustained reductions in suicide rates from awareness campaigns alone is weak.
What did they get wrong (or right)?
The 1,992 figure is close but not precisely sourced, and the creator presents it as if it is a settled daily count rather than a statistical estimate. That matters, because precision in suicide statistics affects policy. The WHO number rounds to roughly 1,926, not 1,992. The difference is small but worth noting in a fact-check context.
They got the trend direction right for college-aged women. This is one of the more robustly documented shifts in recent mental health data. The American College Health Association's 2023 National College Health Assessment found that 44% of college students reported feeling so depressed it was difficult to function, and female students consistently scored worse on nearly every metric.
The claim that suicide rates are rising "every year" is an overstatement. The CDC's most recent data shows rates plateaued slightly in 2020 and 2021 before ticking back up in 2022. The long-term trend is upward, but not every single calendar year shows an increase. That is a small but meaningful mischaracterization of the data.
The broader argument, that a one-month focus creates a false sense of resolution and then abandons people, is supported by qualitative research. Carpiniello and Pinna (2017, Frontiers in Psychiatry) noted that awareness campaigns often increase public discourse without a corresponding increase in accessible care infrastructure.
What should you actually know?
Suicide is not a GLP-1 topic, but it has intersected with GLP-1 drug safety discussions recently. In 2023, the FDA and European Medicines Agency opened investigations into reports of suicidal ideation in patients using semaglutide and liraglutide. As of early 2024, the EMA concluded the available data did not confirm a causal link, but the FDA investigation remained ongoing. If you are on a GLP-1 medication and experiencing mood changes, that is a conversation to have with your prescriber directly.
Back to the video's core point: the structural argument that awareness without access is insufficient is well-supported. A 2022 paper by Niederkrotenthaler et al. in World Psychiatry found that reducing suicide rates requires not just awareness but accessible, affordable mental health services, crisis infrastructure, and means restriction policies. Ribbons do not replace those things.
If you or someone you know is struggling, the 988 Suicide and Crisis Lifeline is available 24/7 by call or text in the United States.
Bottom line
The creator's core statistical claim is approximately correct, their trend data on college women is well-supported, and their skepticism about awareness-month efficacy is grounded in real research. The main errors are minor: the daily death figure is a close estimate rather than a precise count, and "every year" overstates what the trend data actually shows. This is a credible video from someone speaking from lived experience with a generally accurate statistical foundation.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Andrewwwwwwww · TikTok creator
25.7K views on this video
I bet you will not forget that statistic anytime soon…. Hopefully you do something more beyond this month to help yourself or others in the battle against suicide. #suicideprevention #mentalhealth #mentalhealthmatters #mentalhealthawareness
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about who 2021 data estimates roughly 703,000 global suicide deaths per?
WHO 2021 data estimates roughly 703,000 global suicide deaths per year, approximately 1,926 per day, making the 1,992 figure a close but slightly high estimate.
What does the video say about twenge et al. (2018, clinical psychological science) confirmed significant increases?
Twenge et al. (2018, Clinical Psychological Science) confirmed significant increases in suicidal ideation among adolescent and young adult females from 2010 to 2015, validating the college-aged women trend claim.
What does the video say about cdc 2022 data shows the u.s. suicide rate ticked upward?
CDC 2022 data shows the U.S. suicide rate ticked upward after a brief plateau in 2020-2021, meaning 'increasing every year' overstates a real but non-linear long-term trend.
What does the video say about pirkis et al. (2021, the lancet psychiatry) found awareness campaigns?
Pirkis et al. (2021, The Lancet Psychiatry) found awareness campaigns can boost short-term help-seeking but show weak evidence for sustained suicide rate reductions on their own.
What does the video say about samhsa 2022 found 57% of adults who needed mental health?
SAMHSA 2022 found 57% of adults who needed mental health services did not receive them, with cost and provider availability as the leading barriers.
What does the video say about the fda opened an investigation in 2023 into suicidal ideation?
The FDA opened an investigation in 2023 into suicidal ideation reports associated with GLP-1 drugs including semaglutide and liraglutide. The EMA found no confirmed causal link as of early 2024, but the FDA review was still ongoing.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Andrewwwwwwww, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.